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Implementing a registration and analysis of events relating to 
actual or potential unintended exposure 
•       To prepare and deliver guidelines and education 
programmes to enable compliance with national legislation in 
the area 
•       To monitor European and international activities on an 
ongoing basis and update the ESTRO as appropriate 
•       To prepare and disseminate information to the public 
on how safety is already a key focus in radiotherapy generally 
and the on-going efforts to ensure safety issues remain 
central to radiotherapy practice. 
Conclusion: The aim of the task force is to position ESTRO at 
the forefront of Safety and Risk Management in radiation 
therapy by 
•       Collaboration with professional societies within first of 
all in EU/Europe but also with other organisation within RO 
•       Preparation of guidelines and educational material 
 •       Information and dissemination of present and 
future EURATOM directives.  
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of use 
E. Ford1 
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Purpose: Quality and safety improvement is a 
multidimensional problem. Many recommendations for best 
practices have been put forth in the last five years. A recent 
review of seven authoritative documents revealed no fewer 
than 117 separate recommendations. These 
recommendations span the spectrum from quality control to 
prospective risk assessment to incident learning and safety 
culture. With such a wealth of information, it is challenging 
to absorb and implement quality improvement 
recommendations in a busy clinical environment. To address 
this issue, the American Association of Physicists in Medicine 
(AAPM) has developed the Safety Profile Assessment (SPA), a 
freely-available online tool designed to probe key aspects of 
quality and safety. This report describes the development of 
the SPA and its first year of use. 
Methods: The SPA was developed over a two year period by a 
multi-disciplinary panel of experts using a consensus process. 
The resulting tool consists of 92 indicator questions designed 
to gauge the most important dimensions of quality and 
safety. The SPA was pilot tested in 21 volunteer clinics and 
released for general use in July 2013. Anonymous survey data 
were collected to gauge users’ experience. The SPA was also 
analyzed with respect to the widely-accepted dimensions of 
quality from Donabedian. 
Results: In the first year of use, 107 users completed the 
SPA. The online tool provides a (graphical) benchmarking of 
answers against all other respondents in the database and the 
ability to track responses over time. An annotated 
bibliography is available for each indicator question, and the 
user can download a safety and quality tracking spreadsheet 
to guide in the implementation of improvements. Classifying 
the indicator questions according to Donabeian’s quality 
categories yielded the following results: process issues (62%), 
structural issues (27%) and outcomes (8%). In pilot testing the 
SPA required an average of 1.3 hours to complete. The 
majority of respondents (59%) had assembled a 
multidisciplinary group to complete the SPA of 3.9 members 
on average. With a 69% response rate to the survey, 
respondents indicated that SPA was easy or very easy to use 
(70%) and that they would definitely or very probably 
complete the SPA again (63%).  
Conclusions:  The Safety Profile Assessment is a freely 
available online tool intended to provide a practical means 
for assessing the quality and safety environment in a 
radiation oncology clinic. The tool has been reviewed 
favorably by the first cohort of users. 
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Purpose: The goal of the MARR project is to find a means to 
implement a risk analysis methodology among radiotherapy 
professionals. 
This project is coordinated by the Spanish Professional 
Societies of Radiotherapy Oncology (SEOR), Medical Physics 
(SEFM), Radiation Protection (SEPR) and Radiotherapy 
Technologists (AETR).  
Materials and Methods: The risk methodology chosen was the 
simplified dedicated Radiotherapy Risk Matrix and its 
associated software tool SEVRRA, developed by Foro 
Iberoamericano de Organismos Reguladores (FORO). This 
method has been proved in 44 radiotherapy services of 7 
different countries.     
The risk matrix is an easy to use semi quantitative method 
that consists in analyzing all initiating events that can lead to 
an error in the treatment if the measures put in place to 
avoid it (barriers) fail.  As a first stage in the MARR project, 
the initiating events and barriers were adapted to the 
current radiotherapy practice in Spain. 
The risk is defined as a combination of three parameters: the 
frequency of occurrence of the event, the severity of the 
potential consequences and the probability of failure of the 
set of existent barriers. The risk matrix provides the resulting 
risk level from this combination.  
The methodology allows a second deeper analysis on those 
errors resulting in a higher associated risk  
The MARR project was carried out in 10 Spanish Hospitals 
during the period 2013 -2014 and involved: 
- The training of the participating professionals (a working 
team composed by a radiotherapy oncologist –RO-, medical 
physicist –MP- and radiation therapy technologist –RTT- from 
each hospital) in the use of the risk matrix methodology and 
SEVRRA 
- The completion of the risk analysis in every hospital  
- The development of a risk analysis guide based on the 
results and the feedback provided, to facilitate the 
implementation of this method in other hospitals. 
Results: The project is finished. In the following table a list 
of the initiating events, barriers and reducers where some 
modifications were introduced as a consequence of the 
feedback from participating hospitals is shown:   
 
 
The main advantages of the methodology declared by the 
participants are: 
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The main drawbacks are mentioned by a lower percent of 
participants: 
·        There are no institutional support and resources to 
make the analysis (71% of RO, 56% of MP and 33% of RTT). 
·        Time needed (86% of RO, 44% of MP and 50% of RTT). 
·        Very few indicate that it cannot detect the safety weak 
points (14% of RO), results are qualitative and subjective 
(17% of RTT) or that the risk analysis has not the depth 
needed (33% of MP). 
The software used (SEVRRA) was considered as a tool easy to 
use that facilitates the analysis by 71% of RO, 89% of MP and 
67% of RTT. 
Conclusions: The risk matrix is a proven tool for risk analysis 
in radiotherapy.  To implement a risk methodology among 
radiotherapy professionals it is very important that everyone 
who takes part in the process is involved in the risk analysis. 
The working group needs basic training before they can start 
it and assistance from risk analysis experts. 
Training a reduced number of radiotherapy centers, that can 
eventually act as reference centers at local level, is a 
feasible and effective way of spreading the use of these 
techniques at national level. 
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Introduction: Patient safety in radiotherapy is a 
comparatively new discipline that has rapidly risen to star 
status. This rise began in the late 1990s, with eye-opening 
reports documenting the scale of harm caused by medical 
errors. In 2010, the New York Times published a series of 
articles on medical errors elevating the awareness of 
accidents in radiotherapy. Safe radiotherapy requires a multi-
disciplinary comprehensive approach to assure that an 
adequate safety system is in place.  One aspect of a robust 
safety system is the identification of near misses and errors 
that occur in radiotherapy.  The use of an incident learning 
system can capture data that can be used to identify 
weakness in safety and provide the institution with 
information in the use of effective safety barriers. 
Institutions can also look at the potential for harm and 
identify safety infrastructure needs using prospective risk 
analysis such as Failure Mode and Effects Analysis (FMEA). 
These types of analytical tools assist in understanding the 
adequacy of the safety system by addressing the potential for 
errors, the frequency of the errors and the severity of the 
errors. Both reporting and learning systems and prospective 
analysis have value in patient safety, but to elevate their 
effectiveness, the institution should consider looking at 
industry wide activities and results.  Benchmarking can be 
used to compare one institution’s safety system and 
performance metrics to industry standards.  The IAEA Safety 
in Radiation Oncology (SAFRON) Incident Learning system can 
provide both institutional data and global data on potential 
errors.  The system is in the process of implementing a 
prospective risk analysis option that will allow the participant 
to address the likelihood of an event to happen at their 
institution based on initiating events, barriers and 
consequences. 
Purpose/Objective: Provide information of the tools that are 
available to improve safety in radiotherapy, including: 
·   retrospective studies to include incident learning systems, 
·   prospective studies to identify potential for harm, and 
·   use of benchmarking to evaluate safety systems against 
institutional standards. 
Material/methods: Lecture to include demonstration of the 
effectiveness in reducing radiotherapy incidents by 
evaluating past incidents, prospective risk analysis and 
benchmarking. 
Results: Participants will have knowledge on the use of these 
safety tools that can be incorporated into the clinical 
environment and knowledge on how to evaluate their safety 
system. 
Conclusion: A robust safety system in radiotherapy requires a 
multi-disciplinary comprehensive approach that includes 
evaluating events within the institution, evaluating the 
potential for harm and comparing these activities to 
institutional standards in radiotherapy.  This can best be 
accomplished by participating in an incident learning system, 
conducting prospective risk analysis and benchmarking these 
results. 
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The first recorded use of heat to treat cancer was made some 
5000 years ago, thus making it one of the oldest cancer 
therapies known. But, when using heat as a single agent 
therapy, tumour control is only likely when very high thermal 
ablation temperatures are achieved. At lower temperatures 
in the hyperthermia range (typically temperatures of up to 
around 43OC) tumour control is not possible. As a result, 
hyperthermia is often considered an experimental treatment 
with no realistic future in clinical cancer therapy. This is 
wrong. Although hyperthermia per se is probably only useful 
in palliative situations and has no role to play in the curative 
treatment of human tumours, there is definitive evidence 
that when hyperthermia is combined with more conventional 
therapies significant improvements in clinical outcome are 
possible. This is especially true for the combination of 
hyperthermia and radiation, and in fact, hyperthermia is 
probably one of the most effective radiation sensitizers 
known. In this presentation, we will review the pre-clinical 
studies establishing the rationale for how hyperthermia 
should be combined with conventional therapies and present 
an update of the clinical results demonstrating the clear 
benefit of such combination treatments in patients with 
specific types of cancer. In addition, we will discuss what 
approaches are now being applied to further improve the 
efficacy of hyperthermia when combined with more 
conventional therapies. 
